Menu ×


Ready-To-Use Insulin for Intra Venous (IV) Infusion Market Segmentation By Drug Action (Long-Acting Insulin, Rapid Acting Insulin, Premixed Insulin, Others); By End User (Hospitals, Home-Care, Others) - Global Demand Analysis & Opportunity Outlook 2027

  • Text Size:

Extensive insights into the Growth of Ready To Use Insulin for Intra Venous Infusion Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

Introduction to Ready-To-Use Insulin Market

Insulin is a hormone produced by the body in order to control the blood sugar levels. It maintains a low blood sugar by preventing accumulation of glucose in the blood. However, sometimes the body might lose the ability to produce insulin on its own. In such cases, insulin is required from an external source which is given to the patient in the form of intravenous infusions.

The condition caused due to a deficiency of insulin in the body is known as diabetes. Insulin is given to both adults and children suffering from diabetes by injecting the hormone directly into the bloodstream through the veins. Injecting insulin in this manner can be made safer for the patients if the concentration of insulin as well as the quantity is standardized, which reduces the medication errors.

Ready to use insulin for IV infusion provides a consistent and equal dosage of insulin to the patients with every administration, ensuring a faster delivery than alternate methods. It is provided in an urgent medical condition under medical supervision. The ready-to-use insulin can have a shelf life of a month under room temperature and up to 2 years when refrigerated. The longer shelf life of ready-to-use insulin allows it to be easily stored and used as per convenience.

Market Size and Forecast

The market for ready-to-use insulin for IV infusion is mainly driven by the growing number of incidences of diabetes among people of all age groups. Unhealthy dietary habits leading to obesity is another factor which is contributing to the growth of the market.

The ready-to-use insulin for intra venous (IV) infusion market is anticipated to grow at a significant CAGR over the forecast period i.e. 2019-2027. The market is segmented by end user into hospitals, home care and others, out of which, the home care segment is anticipated to hold leading share in the market on account of high prevalence of diabetes among people, mainly those belonging to the older age groups and their preference towards home care. This requires them to use insulin on a regular basis, thus increasing the demand for ready-to-use insulin for IV infusion. CLICK TO DOWNLOAD SAMPLE REPORT

Ready to use Insulin Market Graph

Growth Drivers

Increasing Cases of Obesity Around the World

An unhealthy diet and decreased physical activity among the majority of population are some of the contributing factors behind the growth of this market. The changing lifestyle of people has forced them to adopt unhealthy dietary habits, resulting in disorders such as obesity, which is a leading cause of diabetes. Injecting human insulin through external sources is the only medication for the stabilization and treatment of diabetes and related health conditions. According to W.H.O. (World Health Organization), diabetes was ranked as the seventh leading cause of death that resulted in 1.6 million deaths in 2016. The growing occurrence of diabetes around the globe is anticipated to hone the growth of the market in the coming years.

Faster Mode of Action of Insulin

Ready-to-use insulin, as the name suggests, does not require any preparation prior to use. It can be directly injected into the veins without the addition of any other drug to it. This allows an easy administration of insulin into the body which can be done even at home care facilities under medical supervision.

Rising Research and Development Activities

The high demand for new variants of insulin in the market has led to an expansion of research and development activities in this sector. The leading pharmaceutical companies are being involved in the development and production of such drugs, especially in regions such as North America and the Asia-Pacific. Therefore, a rise in the advancement of the healthcare industry is anticipated to boost the growth of the market.


Time Taken For Approval of Drugs

The approval of drugs requires time and money, which poses as a key restraint to the market growth. An increase in investments, research and development activities in the pharmaceutical sector is required in order to develop and approve the sale of these drugs in the market.

Market Segmentation

Our in-depth analysis of the ready-to-use insulin for intra venous (IV) infusion market includes the following segments:

By Drug Action

  • Long-Acting Insulin
  • Rapid-Acting Insulin
  • Premixed Insulin
  • Others

By End User

  • Hospitals
  • Home Care
  • Others

By Region

On the basis of regional analysis, the ready-to-use insulin for intra venous (IV) infusion market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

On the back of growing number of diabetic patients, the market in North America is anticipated to exhibit maximum growth during the forecast period. According to a report by Centers for Disease Control and Prevention (CDC), the adults living with diabetes or prediabetes is more than 100 million in the U.S. Additionally, the increasing number of hospitals and home care in North America is another factor leading to the growth of this market. This growth is closely trailed by the Asia-Pacific region owing to the rapid development in the healthcare industry combined with increased funding in the pharmaceutical sector.

The ready-to-use insulin for intra venous (IV) infusion market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Operating in the Insulin Market

  • Baxter
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • GlaxoSmithKline
  • Biocon
  • Julphar

Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved